Reviewing ProQR Therapeutics N.V. (PRQR)’s and Clearside Biomedical Inc. (NASDAQ:CLSD)’s results

Both ProQR Therapeutics N.V. (NASDAQ:PRQR) and Clearside Biomedical Inc. (NASDAQ:CLSD) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics N.V. N/A 0.00 N/A -1.29 0.00
Clearside Biomedical Inc. N/A 838.45 77.67M -2.66 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of ProQR Therapeutics N.V. and Clearside Biomedical Inc.

Profitability

Table 2 provides us ProQR Therapeutics N.V. and Clearside Biomedical Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N.V. 0.00% -72.6% -56%
Clearside Biomedical Inc. 0.00% -142.5% -102.8%

Liquidity

ProQR Therapeutics N.V. has a Current Ratio of 11.4 and a Quick Ratio of 11.4. Competitively, Clearside Biomedical Inc.’s Current Ratio is 4.6 and has 4.6 Quick Ratio. ProQR Therapeutics N.V.’s better ability to pay short and long-term obligations than Clearside Biomedical Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for ProQR Therapeutics N.V. and Clearside Biomedical Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ProQR Therapeutics N.V. 0 0 2 3.00
Clearside Biomedical Inc. 0 0 0 0.00

ProQR Therapeutics N.V.’s average price target is $37.5, while its potential upside is 152.36%.

Insider & Institutional Ownership

Roughly 63.5% of ProQR Therapeutics N.V. shares are held by institutional investors while 69.8% of Clearside Biomedical Inc. are owned by institutional investors. About 20.62% of ProQR Therapeutics N.V.’s share are held by insiders. On the other hand, insiders held about 0.3% of Clearside Biomedical Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ProQR Therapeutics N.V. -10.44% -15.07% -8.47% 162.62% 478.64% 429.3%
Clearside Biomedical Inc. -2.04% -34.25% -78.02% -84.98% -76.77% -79.43%

For the past year ProQR Therapeutics N.V. had bullish trend while Clearside Biomedical Inc. had bearish trend.

Summary

ProQR Therapeutics N.V. beats on 7 of the 8 factors Clearside Biomedical Inc.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion (RVO); and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). The companyÂ’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD). Clearside Biomedical, Inc. has a collaboration agreement with Santen Pharmaceutical Co., Ltd. to develop compounds for suprachoroidal space injection that are designed to treat DME, wet AMD, and RVO, as well as to reduce elevated intraocular pressure associated with glaucoma for a sustained period of time. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.